Publications of the Institute of Cell Biology and Immunology

Publications of the Institute

  1. 2023

    1. Müller, D. (2023). Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy. BioDrugs, 37(1), 21--33.
    2. Liang, K. L., Roels, J., Lavaert, M., Putteman, T., Boehme, L., Tilleman, L., Velghe, I., Pegoretti, V., Van de Walle, I., Sontag, S., Vandewalle, J., Vandekerckhove, B., Leclercq, G., Van Vlierberghe, P., Libert, C., Van Nieuwerburgh, F., Fischer, R., Kontermann, R. E., Pfizenmaier, K., … Taghon, T. (2023). Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF. Nature Immunology.
    3. Lungu, C., Meyer, F., Hörning, M., Steudle, J., Braun, A., Noll, B., Benz, D., Fränkle, F., Schmid, S., Eisler, S. A., Olayioye, M. A., & Monilola Olayioye, C. A. (2023). Golgi screen identifies the RhoGEF Solo as a novel regulator of RhoB and endocytic transport. Traffic.
  2. 2022

    1. Hagenlocher, C., Siebert, R., Taschke, B., Wieske, S., Hausser, A., & Rehm, M. (2022). ER stress-induced cell death proceeds independently of the TRAIL-R2 signaling axis in pancreatic β cells. Cell Death Discovery, 8(1), 34.
    2. Ludwig-Słomczyńska, A. H., & Rehm, M. (2022). Mitochondrial genome variations, mitochondrial-nuclear compatibility, and their association with metabolic diseases. Obesity.
    3. Boccellato, C., & Rehm, M. (2022). Glioblastoma, from disease understanding towards optimal cell-based in vitro models. Cellular Oncology.
    4. Del Mistro, G., Riemann, S., Schindler, S., Beissert, S., Kontermann, R. E., Ginolhac, A., Halder, R., Presta, L., Sinkkonen, L., Sauter, T., & Kulms, D. (2022). Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma. Cell Death & Disease, 13(1), 54--54.
    5. Rau, A., Janssen, N., Kühl, L., Sell, T., Kalmykova, S., Mürdter, T. E., Dahlke, M.-H., Sers, C., Morkel, M., Schwab, M., Kontermann, R. E., & Olayioye, M. A. (2022). Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancerTriple HER blockade in CRC. Molecular Cancer Therapeutics.
    6. Aschmoneit, N., Kocher, K., Siegemund, M., Lutz, M. S., Kühl, L., Seifert, O., & Kontermann, R. E. (2022). Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). Oncoimmunology, 11(1), 2028961--2028961.
    7. Frey, Y., Franz-Wachtel, M., Macek, B., & Olayioye, M. A. (2022). Proteasomal turnover of the RhoGAP tumor suppressor DLC1 is regulated by HECTD1 and USP7. Scientific Reports 2022 12:1, 12(1), 1--10.
    8. Bencsik, N., Oueslati Morales, C. O., Hausser, A., & Schlett, K. (2022). Endocytosis of AMPA receptors: Role in neurological conditions. In Progress in Molecular Biology and Translational Science. Academic Press.
    9. Guttà, C., Morhard, C., & Rehm, M. (2022). Applying GAN-based data augmentation to improve transcriptome-based prognostication in breast cancer. In medRxiv. Cold Spring Harbor Laboratory Press.
    10. Seifert, O., & Kontermann, R. E. (2022). GlycoTAIL and FlexiTAIL as Half-Life Extension Modules for Recombinant Antibody Fragments. Molecules (Basel, Switzerland), 27(10), 3272--.
    11. Guttà, C., Morhard, C., & Rehm, M. (2022). T-GAN-D: a GAN-based classifier for breast cancer                    prognostication. Zenodo.
    12. Kühl, L., Aschmoneit, N., Kontermann, R. E., & Seifert, O. (2022). The eIg technology to generate Ig-like bispecific antibodies. MAbs, 14(1), 2063043.
    13. Müller, D. (2022). Optimized CD19/CD22/CD3 antibody. Blood, 140(16), 1750–1751.
    14. Mora-Molina, R., Stöhr, D., Rehm, M., & López-Rivas, A. (2022). cFLIP downregulation is an early event required for endoplasmic reticulum stress-induced apoptosis in tumor cells. Cell Death & Disease, 13(2), 111.
    15. Vera, J., Lai, X., Baur, A., Erdmann, M., Gupta, S., Guttà, C., Heinzerling, L., Heppt, M. V., Kazmierczak, P. M., Kunz, M., Lischer, C., Pützer, B. M., Rehm, M., Ostalecki, C., Retzlaff, J., Witt, S., Wolkenhauer, O., & Berking, C. (2022). Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence. Briefings in Bioinformatics.
    16. Dilchert, J., Hofmann, M., Unverdorben, F., Kontermann, R., & Bunk, S. (2022). Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules. Antibodies, 11(2), Article 2.
  3. 2021

    1. Lindner, A. U., Salvucci, M., McDonough, E., Cho, S., Stachtea, X., O’Connell, E. P., Corwin, A. D., Santamaria-Pang, A., Carberry, S., Fichtner, M., Van Schaeybroeck, S., Laurent-Puig, P., Burke, J. P., McNamara, D. A., Lawler, M., Sood, A., Graf, J. F., Rehm, M., Dunne, P. D., … Prehn, J. H. M. (2021). An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell Death & Differentiation.
    2. Juric, V., Hudson, L., Fay, J., Richards, C. E., Jahns, H., Verreault, M., Bielle, F., Idbaih, A., Lamfers, M. L. M., Hopkins, A. M., Rehm, M., & Murphy, B. M. (2021). Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death & Disease 2021 12:8, 12(8), 1--12.
    3. Brinkmann, U., & Kontermann, R. E. (2021). Bispecific antibodies. Science, 372(6545), 916--917.
    4. Kontermann, R. E., Ungerechts, G., & Nettelbeck, D. M. (2021). Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. MAbs, 13(1), 1982447--1982447.
    5. Aschmoneit, N., Steinlein, S., Kühl, L., Seifert, O., & Kontermann, R. E. (2021). A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Scientific Reports, 11(1), 13880.
    6. Bethea, J. R., & Fischer, R. (2021). Role of peripheral immune cells for development and recovery of chronic pain. Frontiers in Immunology, 12.
    7. Pollak, N., Lindner, A., Imig, D., Kuritz, K., Fritze, J. S., Decker, L., Heinrich, I., Stadager, J., Eisler, S., Stöhr, D., Allgöwer, F., Scheurich, P., & Rehm, M. (2021). Cell cycle progression and transmitotic apoptosis resistance promote escape from extrinsic apoptosis. Journal of Cell Science, jcs.258966--.
    8. Boccellato, C., Kolbe, E., Peters, N., Juric, V., Fullstone, G., Verreault, M., Idbaih, A., Lamfers, M. L. M., Murphy, B. M., & Rehm, M. (2021). Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. Cell Death & Disease, 12(7), 647.
    9. Massafra, V., Tundo, S., Dietzig, A., Ducret, A., Jost, C., Klein, C., Kontermann, R. E., Knoetgen, H., Steegmaier, M., Romagnani, A., & Nagel, Y. A. (2021). Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells. The Journal of Immunology.
    10. Juric, V., Düssmann, H., Lamfers, M. L. M., Prehn, J. H. M., Rehm, M., & Murphy, B. M. (2021). Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM. Cells 2021, Vol. 10, Page 1182, 10(5), 1182.
    11. Rau, A., Kocher, K., Rommel, M., Kühl, L., Albrecht, M., Gotthard, H., Aschmoneit, N., Noll, B., Olayioye, M. A., Kontermann, R. E., & Seifert, O. (2021). A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3. MAbs, 13(1), 1902034.
    12. Aschmoneit, N., Kühl, L., Seifert, O., & Kontermann, R. E. (2021). Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. Journal for Immunotherapy of Cancer, 9(11), e003616--.
    13. Siegemund, M., Oak, P., Hansbauer, E.-M., Allersdorfer, A., Utschick, K., Winter, A., Grasmüller, C., Galler, G., Mayer, J.-P., Weiche, B., Prassler, J., Kontermann, R. E., & Rothe, C. (2021). Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains. Frontiers in Pharmacology, 12, 759337--759337.
    14. Oueslati Morales, C. O., Ignácz, A., Bencsik, N., Sziber, Z., Rátkai, A. E., Lieb, W. S., Eisler, S. A., Szűcs, A., Schlett, K., & Hausser, A. (2021). Protein Kinase D promotes activity-dependent AMPA receptor endocytosis in hippocampal neurons. Traffic, n/a(n/a), Article n/a.
    15. McCann, C., Matveeva, A., McAllister, K., Sessler, T., Fichtner, M., Carberry, S., Rehm, M., Prehn, J. H. M., & Longley, D. B. (2021). Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer. The FEBS Journal, febs.15801.
    16. Krishna Moorthy, N., Seifert, O., Eisler, S., Weirich, S., Kontermann, R. E., Rehm, M., & Fullstone, G. (2021). Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma. Molecules 2021, Vol. 26, Page 7582, 26(24), 7582.
    17. Papazian, I., Tsoukala, E., Boutou, A., Karamita, M., Kambas, K., Iliopoulou, L., Fischer, R., Kontermann, R. E., Denis, M. C., Kollias, G., Lassmann, H., & Probert, L. (2021). Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKKβ promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice. Journal of Neuroinflammation, 18(1), 222--222.
    18. Richter, F., Williams, S. K., John, K., Huber, C., Vaslin, C., Zanker, H., Fairless, R., Pichi, K., Marhenke, S., Vogel, A., Dhaen, M.-A., Herrmann, S., Herrmann, A., Pfizenmaier, K., Bantel, H., Diem, R., Kontermann, R. E., & Fischer, R. (2021). The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. Frontiers in Immunology, 12.
    19. Ehlers, W., Morrison (Rehm), M., Schröder, P., Stöhr, D., & Wagner, A. (2021). Multiphasic modelling and computation of metastatic lung-cancer cell proliferation and atrophy in brain tissue based on experimental data. Biomechanics and Modeling in Mechanobiology.
    20. Hellwig, C. T., Delgado, M. E., Skoko, J., Dyck, L., Hanna, C., Wentges, A., Langlais, C., Hagenlocher, C., Mack, A., Dinsdale, D., Cain, K., MacFarlane, M., & Rehm, M. (2021). Proteasome inhibition triggers the formation of TRAIL receptor 2 platforms for caspase-8 activation that accumulate in the cytosol. Cell Death & Differentiation 2021, 1--9.
  4. 2020

    1. Khawaja, H., Campbell, A., Roberts, J. Z., Javadi, A., O’Reilly, P., McArt, D., Allen, W. L., Majkut, J., Rehm, M., Bardelli, A., Di Nicolantonio, F., Scott, C. J., Kennedy, R., Vitale, N., Harrison, T., Sansom, O. J., Longley, D. B., Evergren, E., & Van Schaeybroeck, S. (2020). RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death & Disease, 11(10), 930--.
    2. Kuritz, K., Stöhr, D., Maichl, D. S., Pollak, N., Rehm, M., & Allgöwer, F. (2020). Reconstructing temporal and spatial dynamics from single-cell pseudotime using prior knowledge of real scale cell densities. Scientific Reports, 10(1), 3619.
    3. Fullstone, G., Guttà, C., Beyer, A., & Rehm, M. (2020). The FLAME-accelerated signalling tool (FaST) for facile parallelisation of flexible agent-based models of cell signalling. Npj Systems Biology and Applications, 6(1), 10--.
    4. Sapski, S., Beha, N., Kontermann, R. E., & Müller, D. (2020). Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response. Cancer Immunol Immunother.
    5. Stöhr, D., Schmid, J. O., Beigl, T. B., Mack, A., Maichl, D. S., Cao, K., Budai, B., Fullstone, G., Kontermann, R. E., Mürdter, T. E., Tait, S. W. G., Hagenlocher, C., Pollak, N., Scheurich, P., & Rehm, M. (2020). Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death & Differentiation, 27, 3037–3052.
    6. Pegoretti, V., Swanson, K. A., Bethea, J. R., Probert, L., Eisel, U. L. M., & Fischer, R. (2020). Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. Oxidative Medicine and Cellular Longevity, 2020, 19.
    7. Sánchez-González, I., Bobien, A., Molnar, C., Schmid, S., Strotbek, M., Boerries, M., Busch, H., & Olayioye, M. A. (2020). miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. Cancer Research, canres.1934.2019.
    8. Vetma, V., Guttà, C., Peters, N., Praetorius, C., Hutt, M., Seifert, O., Meier, F., Kontermann, R., Kulms, D., & Rehm, M. (2020). Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism. Cell Death & Differentiation 2020, 1--16.
    9. Müller, I., Strozyk, E., Schindler, S., Beissert, S., Oo, H. Z., Sauter, T., Lucarelli, P., Raeth, S., Hausser, A., Al Nakouzi, N., Fazli, L., Gleave, M. E., Liu, H., Simon, H.-U., Walczak, H., Green, D. R., Bartek, J., Daugaard, M., & Kulms, D. (2020). Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Molecular Cell.
    10. Stöhr, D., Jeltsch, A., & Rehm, M. (2020). TRAIL receptor signaling: From the basics of canonical signal transduction toward its entanglement with ER stress and the unfolded protein response. Int Rev Cell Mol Biol, 351, 57–99.
    11. Guttà, C., Rahman, A., Aura, C., Dynoodt, P., Charles, E. M., Hirschenhahn, E., Joseph, J., Wouters, J., de Chaumont, C., Rafferty, M., Warren, M., van den Oord, J. J., Gallagher, W. M., & Rehm, M. (2020). Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma. Cell Death & Disease, 11(2), 124.
    12. Rau, A., Lieb, W. S., Seifert, O., Honer, J., Birnstock, D., Richter, F., Aschmoneit, N., Olayioye, M. A., & Kontermann, R. E. (2020). Inhibition of tumor cell growth and cancer stem cell expansion by a bispecific antibody targeting EGFR and HER3. Mol Cancer Ther.
    13. White, K., Connor, K., Clerkin, J., Murphy, B. M., Salvucci, M., O’Farrell, A. C., Rehm, M., O’Brien, D., Prehn, J. H. M., Niclou, S. P., Lamfers, M. L. M., Verreault, M., Idbaih, A., Verhaak, R., Golebiewska, A., & Byrne, A. T. (2020). New hints towards a precision medicine strategy for IDH wild-type Glioblastoma. Annals of Oncology.
    14. Fischer, R., Kontermann, R. E., & Pfizenmaier, K. (2020). Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. Front Cell Dev Biol, 8, 401–401.
    15. Hartung, F., Krüwel, T., Shi, X., Pfizenmaier, K., Kontermann, R., Chames, P., Alves, F., & Pardo, L. A. (2020). A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells. Front Pharmacol, 11, 686–686.
    16. Pacheco-Fernandez, N., Pakdel, M., Blank, B., Sanchez-Gonzalez, I., Weber, K., Tran, M. L., Hecht, T. K.-H., Gautsch, R., Beck, G., Perez, F., Hausser, A., Linder, S., & von Blume, J. (2020). Nucleobindin-1 regulates ECM degradation by promoting intra-Golgi trafficking of MMPs. Journal of Cell Biology, 219(8), Article 8.
    17. Imig, D., Pollak, N., Allgöwer, F., & Rehm, M. (2020). Sample-based modeling reveals bidirectional interplay between cell cycle progression and extrinsic apoptosis. PLOS Computational Biology, 16(6), 1–17.
    18. Stöhr, D., & Rehm, M. (2020). Linking hyperosmotic stress and apoptotic sensitivity. The FEBS Journal, febs.15520.
    19. Fabre, M., Ferrer, C., Dominguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., Eisler, S. A., Kontermann, R. E., Pfizenmaier, K., Lee, S. Y., dM Vivanco, M., Lopez-Casas, P. P., Perea, S., Abbas, M., Richter, W., Simón, L., & Hidalgo, M. (2020). OMTX705, a Novel FAP-Targeting ADC demonstrates Activity in Chemotherapy and PD1-Resistant Solid Tumors Models. Clinical Cancer Research, clincanres.2238.2019.
    20. Wandrer, F., Liebig, S., Marhenke, S., Vogel, A., John, K., Manns, M. P., Teufel, A., Itzel, T., Longerich, T., Maier, O., Fischer, R., Kontermann, R. E., Pfizenmaier, K., Schulze-Osthoff, K., & Bantel, H. (2020). TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis, 11(3), 212–212.
    21. Tansi, F. L., Rüger, R., Kollmeier, A. M., Rabenhold, M., Steiniger, F., Kontermann, R. E., Teichgräber, U. K., Fahr, A., & Hilger, I. (2020). Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes. Pharmaceutics, 12(4), 370.
    22. Fullstone, G., Bauer, T. L., Guttà, C., Salvucci, M., Prehn, J. H. M., & Rehm, M. (2020). The apoptosome molecular timer synergises with XIAP to suppress apoptosis execution and contributes to prognosticating survival in colorectal cancer. Cell Death & Differentiation.
    23. Zhang, S., Liu, H., Yin, M., Pei, X., Hausser, A., Ishikawa, E., Yamasaki, S., & Jin, Z. G. (2020). Deletion of Protein Kinase D3 Promotes Liver Fibrosis in Mice. Hepatology, hep.31176.
  5. 2019

    1. Olayioye, M. A., Noll, B., & Hausser, A. (2019). Spatiotemporal Control of Intracellular Membrane Trafficking by Rho GTPases. Cells, 8(12), 1478.
    2. Salvucci, M., Rahman, A., Resler, A. J., Udupi, G. M., McNamara, D. A., Kay, E. W., Laurent-Puig, P., Longley, D. B., Johnston, P. G., Lawler, M., Wilson, R., Salto-Tellez, M., Van Schaeybroeck, S., Rafferty, M., Gallagher, W. M., Rehm, M., & Prehn, J. H. M. (2019). A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. JCO Clinical Cancer Informatics, 3, 1--17.
    3. Podder, B., Guttà, C., Rožanc, J., Gerlach, E., Feoktistova, M., Panayotova-Dimitrova, D., Alexopoulos, L. G., Leverkus, M., & Rehm, M. (2019). TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma. Cell Death & Differentiation, 1.
    4. Richter, F., Seifert, O., Herrmann, A., Pfizenmaier, K., & Kontermann, R. E. (2019). Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc. MAbs, 1--13.
    5. Beha, N., Harder, M., Ring, S., Kontermann, R. E., & Müller, D. (2019). IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands in the single-chain format for cancer immunotherapy. Molecular Cancer Therapeutics, molcanther.1204.2018.
    6. von Blume, J., & Hausser, A. (2019). Lipid‐dependent coupling of secretory cargo sorting and trafficking at the trans‐Golgi network. FEBS Letters, 1873--3468.13552.
    7. Fischer, R., Padutsch, T., Bracchi-Ricard, V., Murphy, K. L., Martinez, George. F., Delguercio, N., Elmer, N., Sendetski, M., Diem, R., Eisel, U. L. M., Smeyne, R. J., Kontermann, R. E., Pfizenmaier, K., & Bethea, J. R. (2019). Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis. Brain, Behavior, and Immunity.
    8. Schrade, A., Bujotzek, A., Spick, C., Wagner, M., Goerl, J., Wezler, X., Georges, G., Kontermann, R. E., & Brinkmann, U. (2019). Back-To-Germline (B2G) Procedure for Antibody Devolution. Antibodies, 8(3), 45.
    9. Skoko, J., Rožanc, J., Charles, E. M., Alexopoulos, L. G., & Rehm, M. (2019). Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma. BMC Cell Biology, 19(1), 28.
    10. Noonan, J. J., Jarzabek, M., Lincoln, F. A., Cavanagh, B. L., Pariag, A. R., Juric, V., Young, L. S., Ligon, K. L., Jahns, H., Zheleva, D., Prehn, J. H. M., Rehm, M., Byrne, A. T., & Murphy, B. M. (2019). Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers (Basel), 11(12), Article 12.
    11. Kleih, M., Böpple, K., Dong, M., Gaißler, A., Heine, S., Olayioye, M. A., Aulitzky, W. E., & Essmann, F. (2019). Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death & Disease, 10(11), 851.
    12. Fischer, R., Sendetski, M., Del Rivero, T., Martinez, G. F., Bracchi-Ricard, V., Swanson, K. A., Pruzinsky, E. K., Delguercio, N., Rosalino, M. J., Padutsch, T., Kontermann, R. E., Pfizenmaier, K., & Bethea, J. R. (2019). TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes. Proceedings of the National Academy of Sciences of the United States of America, 116(34), 17045--17050.
    13. Tsur, N., Kogan, Y., Rehm, M., & Agur, Z. (2019). Response of Patients with Melanoma to Immune Checkpoint Blockade – Insights Gleaned from Analysis of a New Mathematical Mechanistic Model. Journal of Theoretical Biology, 110033.
    14. Lieb, W. S., Lungu, C., Tamas, R., Berreth, H., Rathert, P., Storz, P., Olayioye, M. A., & Hausser, A. (2019). The GEF‐H1/PKD3 signaling pathway promotes the maintenance of triple negative breast cancer stem cells. International Journal of Cancer, ijc.32798.
    15. Seifert, O., Rau, A., Beha, N., Richter, F., & Kontermann, R. E. (2019). Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. MAbs, 19420862.2019.1603024.
    16. Noll, B., Benz, D., Frey, Y., Meyer, F., Lauinger, M., Eisler, S. A., Schmid, S., Hordijk, P. L., & Olayioye, M. A. (2019). DLC3 suppresses MT1-MMP-dependent matrix degradation by controlling RhoB and actin remodeling at endosomal membranes. Journal of Cell Science, jcs.223172.
    17. Padutsch, T., Maksim, S., Huber, C., Peters, N., Pfizenmaier, K., Bethea, J. R., Kontermann, R. E., & Fischer, R. (2019). Superior Treg-expanding properties of a novel dual-acting cytokine fusion protein. Frontiers in Pharmacology, 10, 1490.
  6. 2018

    1. Tansi, F. L., Rüger, R., Kollmeier, A. M., Rabenhold, M., Steiniger, F., Kontermann, R. E., Teichgraeber, U. K., Fahr, A., & Hilger, I. (2018). Endoglin based  in vivo  near-infrared fluorescence imaging of tumor models in mice using activatable liposomes. Biochimica et Biophysica Acta (BBA) - General Subjects.
    2. Richter, F., Zettlitz, K. A., Seifert, O., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2018). Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity. MAbs, 19420862.2018.1524664.
    3. Williams, S. K., Fairless, R., Maier, O., Liermann, P. C., Pichi, K., Fischer, R., Eisel, U. L. M., Kontermann, R., Herrmann, A., Weksler, B., Romero, N., Couraud, P.-O., Pfizenmaier, K., & Diem, R. (2018). Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Scientific Reports, 8(1), 13628.
    4. Hantusch, A., Rehm, M., & Brunner, T. (2018). Counting on Death - Quantitative aspects of Bcl-2 family regulation. The FEBS Journal.
    5. Rožanc, J., Sakellaropoulos, T., Antoranz, A., Guttà, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., Kulms, D., Rehm, M., & Alexopoulos, L. (2018). Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma. Cell Death & Differentiation, 1.
    6. Chen, M., Urs, M. J., Sánchez-González, I., Olayioye, M. A., Herde, M., & Witte, C.-P. (2018). m6A RNA Degradation Products are Catabolized by an Evolutionarily Conserved N6-methyl-AMP Deaminase in Plant and Mammalian Cells. The Plant Cell, tpc.00236.2018.
    7. Del Mistro, G., Lucarelli, P., Müller, I., De Landtsheer, S., Zinoveva, A., Hutt, M., Siegemund, M., Kontermann, R. E., Beissert, S., Sauter, T., & Kulms, D. (2018). Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma. Npj Systems Biology and Applications, 4(1), 39.
    8. Jensch, A., Frey, Y., Bitschar, K., Weber, P., Schmid, S., Hausser, A., Olayioye, M. A., & Radde, N. E. (2018). The tumor suppressor protein DLC1 maintains protein kinase D activity and Golgi secretory function. Journal of Biological Chemistry, jbc.RA118.003787.
    9. Eisler, S. A., Curado, F., Link, G., Schulz, S., Noack, M., Steinke, M., Olayioye, M. A., & Hausser, A. (2018). A Rho signaling network links microtubules to PKD controlled carrier transport to focal adhesions. ELife, 7.
    10. Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., Annicchiarico-Petruzzelli, M., Antonov, A. V., Arama, E., Baehrecke, E. H., Barlev, N. A., Bazan, N. G., Bernassola, F., Bertrand, M. J. M., Bianchi, K., … Kroemer, G. (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death & Differentiation.
    11. Lincoln, F. A., Imig, D., Boccellato, C., Juric, V., Noonan, J., Kontermann, R. E., Allgöwer, F., Murphy, B. M., & Rehm, M. (2018). Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism. Cell Death & Disease, 9(11), 1112.
    12. Fellermeier-Kopf, S., Gieseke, F., Sahin, U., Müller, D., Pfizenmaier, K., & Kontermann, R. E. (2018). Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. OncoImmunology, 7(9), e1471442.
    13. Carberry, S., D’Orsi, B., Monsefi, N., Salvucci, M., Bacon, O., Fay, J., Rehm, M., McNamara, D., Kay, E. W., & Prehn, J. M. H. (2018). The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer. Cell Death & Disease, 9(2), 125--.
    14. Siegemund, M., Schneider, F., Hutt, M., Seifert, O., Müller, I., Kulms, D., Pfizenmaier, K., & Kontermann, R. E. (2018). IgG-single-chain TRAIL fusion proteins for tumour therapy. Scientific Reports, 8(1), 7808.
    15. Apweiler, R., Beissbarth, T., Berthold, M. R., Blüthgen, N., Burmeister, Y., Dammann, O., Deutsch, A., Feuerhake, F., Franke, A., Hasenauer, J., Hoffmann, S., Höfer, T., Jansen, P. L., Kaderali, L., Klingmüller, U., Koch, I., Kohlbacher, O., Kuepfer, L., Lammert, F., … Wolkenhauer, O. (2018). Whither systems medicine? Experimental &Amp; Molecular Medicine, 50, e453--.
    16. Hutt, M., Fellermeier-Kopf, S., Seifert, O., Schmitt, L. C., Pfizenmaier, K., & Kontermann, R. E. (2018). Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells. Oncotarget, 9(13), 11322--11335.
    17. Almanza, A., Carlesso, A., Chintha, C., Creedican, S., Doultsinos, D., Leuzzi, B., Luís, A., McCarthy, N., Montibeller, L., More, S., Papaioannou, A., Püschel, F., Sassano, M. L., Skoko, J., Agostinis, P., de Belleroche, J., Eriksson, L. A., Fulda, S., Gorman, A. M., … Samali, A. (2018). Endoplasmic Reticulum Stress signalling - from basic mechanisms to clinical applications. The FEBS Journal.
    18. Satta, A., Mezzanzanica, D., Caroli, F., Frigerio, B., Nicola, M. D., Kontermann, R. E., Iacovelli, F., Desideri, A., Anichini, A., Canevari, S., Gianni, A. M., & Figini, M. (2018). Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs, 19420862.2018.1494105.
    19. Fischer, R., Proske, M., Duffey, M., Stangl, H., Martinez, G. F., Peters, N., Kraske, A., Straub, R. H., Bethea, J. R., Kontermann, R. E., & Pfizenmaier, K. (2018). Selective activation of tumor necrosis factor receptor 2 induces anti-inflammatory responses and alleviates experimental arthritis. Arthritis & Rheumatology.
    20. Crawford, N., Salvucci, M., Hellwig, C. T., Lincoln, F. A., Mooney, R. E., O’Connor, C. L., Prehn, J. H., Longley, D. B., & Rehm, M. (2018). Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711. Cell Death & Differentiation.
    21. Hantusch, A., Das, K. K., García-Sáez, A. J., Brunner, T., & Rehm, M. (2018). Bax retrotranslocation potentiates Bcl-xL’s antiapoptotic activity and is essential for switch-like transitions between MOMP competency and resistance. Cell Death & Disease, 9(4), 430.
    22. Puerto-Camacho, P., Amaral, A. T., Lamhamedi-Cherradi, S.-E., Menegaz, B. A., Castillo-Ecija, H., Ordóñez, J. L., Dominguez-Hormaetxe, S., Jordan-Perez, C., Diaz-Martin, J., Romero-Pérez, L., Lopez-Alvarez, M., Civantos-Jubera, G., Robles-Frias, M. J., Biscuola, M., Ferrer, C., Mora, J., Cuglievan, B., Schadler, K. L., Seifert, O., … de Álava, E. (2018). Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma. Clinical Cancer Research, clincanres.0936.2018.
    23. Danish, L., Imig, D., Allgöwer, F., Scheurich, P., & Pollak, N. (2018). Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLOS ONE, 13(6), 1–19.
  7. 2017

    1. Kuritz, K., Stöhr, D., Pollak, N., & Allgöwer, F. (2017). On the relationship between cell cycle analysis with ergodic principles and age-structured cell population models. Journal of Theoretical Biology, 414, 91--102.
    2. Strotbek, M., Schmid, S., Sánchez-González, I., Boerries, M., Busch, H., & Olayioye, M. A. (2017). miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. International Journal of Cancer, 140(10), 2310--2320.
    3. Hantusch, A., Brunner, T., Frickey, T., & Rehm, M. (2017). Bcl-2-Ome-a database and interactive web service for dissecting the Bcl-2 interactome. Cell Death and Differentiation, 24(1), 192.
    4. Hutt, M., Marquardt, L., Seifert, O., Siegemund, M., Müller, I., Kulms, D., Pfizenmaier, K., & Kontermann, R. E. (2017). Superior properties of Fc-comprising scTRAIL fusion proteins. Molecular Cancer Therapeutics, 16(12), molcanther.0551.2017.
    5. Brinkmann, U., & Kontermann, R. E. (2017). The making of bispecific antibodies. MAbs, 9(2), 182--212.
    6. Fischer, R., Marsal, J., Guttà, C., Eisler, S. A., Peters, N., Bethea, J. R., Pfizenmaier, K., & Kontermann, R. E. (2017). Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Scientific Reports, 7(1), 6607.
    7. Schmitt, L. C., Rau, A., Seifert, O., Honer, J., Hutt, M., Schmid, S., Zantow, J., Hust, M., Dübel, S., Olayioye, M. A., & Kontermann, R. E. (2017). Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs, 9(5), 831--843.
    8. Capasso, S., Sticco, L., Rizzo, R., Pirozzi, M., Russo, D., Dathan, N. A., Campelo, F., van Galen, J., Hölttä‐Vuori, M., Turacchio, G., Hausser, A., Malhotra, V., Riezman, I., Riezman, H., Ikonen, E., Luberto, C., Parashuraman, S., Luini, A., & D’Angelo, G. (2017). Sphingolipid metabolic flow controls phosphoinositide turnover at the \textlessi\textgreatertrans\textless/i\textgreater ‐Golgi network. The EMBO Journal, 36(12), 1736--1754.
    9. Pieper, L. A., Strotbek, M., Wenger, T., Olayioye, M. A., & Hausser, A. (2017). ATF6β-based fine-tuning of the unfolded protein response enhances therapeutic antibody productivity of Chinese hamster ovary cells. Biotechnology and Bioengineering, 114(6), 1310--1318.
    10. Sapski, S., Beha, N., Kontermann, R., & Müller, D. (2017). Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. OncoImmunology, 6(12), e1361594.
    11. Schröder, P., Wagner, A., Stöhr, D., Rehm, M., & Ehlers, W. (2017). Data-driven simulation of metastatic processes within brain tissue. PAMM, 17(1), 221--222.
    12. Salvucci, M., Urstle, M. L., Morgan, C., Curry, S., Cremona, M., Lindner, A. U., Bacon, O., Resler, A. J., Murphy, A. C., O’Byrne, R., Flanagan, L., Dasgupta, S., Rice, N., Pilati, C., Zink, E., Scholler, L. M., Toomey, S., Lawler, M., Johnston, P. G., … Prehn, J. H. M. (2017). A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer. Clinical Cancer Research, 23(5), 1200--1212.
    13. Lakner, P. H., Monaghan, M. G., Möller, Y., Olayioye, M. A., & Schenke-Layland, K. (2017). Applying phasor approach analysis of multiphoton FLIM measurements to probe the metabolic activity of three-dimensional in vitro cell culture models. Scientific Reports, 7, 42730.
    14. Vetma, V., Rozanc, J., Charles, E. M., Hellwig, C. T., Alexopoulos, L. G., & Rehm, M. (2017). Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 25(9), 1489--1494.
    15. Hausser, A., & Schlett, K. (2017). Coordination of AMPA receptor trafficking by Rab GTPases. Small GTPases, 1--14.
    16. Pieper, L. A., Strotbek, M., Wenger, T., Gamer, M., Olayioye, M. A., & Hausser, A. (2017). Secretory pathway optimization of CHO producer cells by co-engineering of the mitosRNA-1978 target genes CerS2 and Tbc1D20. Metabolic Engineering, 40, 69--79.
  8. 2016

    1. Hendrick, J., Franz-Wachtel, M., Moeller, Y., Schmid, S., Macek, B., & Olayioye, M. A. (2016). The polarity protein Scribble positions DLC3 at adherens junctions to regulate Rho signaling. Journal of Cell Science, 129(19), 3583--3596.
    2. Möller, Y., Morkel, M., Schmid, J., Beyes, S., Hendrick, J., Strotbek, M., Riemer, P., Schmid, S., Schmitt, L. C., Kontermann, R., Mürdter, T., Schwab, M., Sers, C., & Olayioye, M. a. (2016). Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget, 7(33), 53526--53539.
    3. Tansi, F. L., Rüger, R., Böhm, C., Kontermann, R. E., Teichgraeber, U. K., Fahr, A., & Hilger, I. (2016). Potential of activatable FAP-targeting immunoliposomes in intraoperative imaging of spontaneous metastases. Biomaterials, 88, 70--82.
    4. Unverdorben, F., Richter, F., Hutt, M., Seifert, O., Malinge, P., Fischer, N., & Kontermann, R. E. (2016). Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs, 8(1), 120--128.
    5. Szíber, Z., Liliom, H., Morales, C. O. O., Ignácz, A., Rátkai, A. E., Ellwanger, K., Link, G., Szűcs, A., Hausser, A., & Schlett, K. (2016). Ras and Rab interactor 1 controls neuronal plasticity by coordinating dendritic filopodial motility and AMPA receptor turnover. Molecular Biology of the Cell, 28(2), mbc.E16--07--0526.
    6. Dong, Y., Fischer, R., Naudé, P. J. W., Maier, O., Nyakas, C., Duffey, M., Van der Zee, E. A., Dekens, D., Douwenga, W., Herrmann, A., Guenzi, E., Kontermann, R. E., Pfizenmaier, K., & Eisel, U. L. M. (2016). Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proceedings of the National Academy of Sciences, 113(43), 12304--12309.
    7. Fiedler, A., Raeth, S., Theis, F. J., Hausser, A., & Hasenauer, J. (2016). Tailored parameter optimization methods for ordinary differential equation models with steady-state constraints. BMC Systems Biology, 10(1), 80.
    8. Weyhenmeyer, B. C., Noonan, J., Würstle, M. L., Lincoln, F. A., Johnston, G., Rehm, M., & Murphy, B. M. (2016). Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget, 7(38), 61295--61311.
    9. Hendrick, J., & Olayioye, M. A. (2016). Spatial Rho regulation: Molecular mechanisms controlling the GAP protein DLC3. Small GTPases, 1--7.
    10. Fellermeier, S., Beha, N., Meyer, J. E., Ring, S., Bader, S., Kontermann, R. E., & Müller, D. (2016). Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. OncoImmunology, 5(11), e1238540.
    11. Kälble, F., Damaske, J., Heide, D., Arnold, I., Richter, F., Maier, O., Eisel, U., Scheurich, P., Pfizenmaier, K., Zeier, M., Schwenger, V., & Ranzinger, J. (2016). Selective blocking of TNF receptor 1 attenuates peritoneal dialysis fluid induced inflammation of the peritoneum in mice. PLoS ONE, 11(10), e0163314.
    12. Siegemund, M., Seifert, O., Zarani, M., Dzinić, T., De Leo, V., Göttsch, D., Münkel, S., Hutt, M., Pfizenmaier, K., & Kontermann, R. E. (2016). An optimized antibody-single-chain TRAIL fusion protein for cancer therapy. MAbs, 8(5), 879--891.
    13. Kontermann, R. E. (2016). Half-life extended biotherapeutics. Expert Opinion on Biological Therapy, 16(7), 903--915.
  9. 2015

    1. Tárnok, K., Gulyás, M., Bencsik, N., Ferenc, K., Pfizenmaier, K., Hausser, A., & Schlett, K. (2015). A new tool for the quantitative analysis of dendritic filopodial motility. Cytometry Part A, 87(1), 89--96.
    2. Fernández-Ulibarri, I., Hammer, K., Arndt, M. A. E., Kaufmann, J. K., Dorer, D., Engelhardt, S., Kontermann, R. E., Hess, J., Allgayer, H., Krauss, J., & Nettelbeck, D. M. (2015). Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. International Journal of Cancer, 136(9), 2228--2240.
    3. Weber, P., Hornjik, M., Olayioye, M. A., Hausser, A., & Radde, N. E. (2015). A computational model of PKD and CERT interactions at the trans-Golgi network of mammalian cells. BMC Systems Biology, 9(1), 9.
    4. Wortzel, I., Hanoch, T., Porat, Z., Hausser, A., & Seger, R. (2015). Mitotic Golgi translocation of ERK1c is mediated by PI4KIIIβ/14-3-3γ shuttling complex. Journal of Cell Science, 204(22), jcs.170910--.
    5. Kontermann, R. E., & Brinkmann, U. (2015). Bispecific antibodies. Drug Discovery Today, 20(7), 838--847.
    6. Braun, A. C., & Olayioye, M. A. (2015). Rho regulation: DLC proteins in space and time. Cellular Signalling, 27(8), 1643--1651.
    7. Fischer, R., Kontermann, R., & Maier, O. (2015). Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. Antibodies, 4(1), 48--70.
    8. Kang, B., Okwieka, P., Schöttler, S., Seifert, O., Kontermann, R. E., Pfizenmaier, K., Musyanovych, A., Meyer, R., Diken, M., Sahin, U., Mailänder, V., Wurm, F. R., & Landfester, K. (2015). Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials, 49, 125--134.
    9. Bencsik, N., Szíber, Z., Liliom, H., Tárnok, K., Borbély, S., Gulyás, M., Rátkai, A., Szucs, A., Hazai-Novák, D., Ellwanger, K., Rácz, B., Pfizenmaier, K., Hausser, A., & Schlett, K. (2015). Protein kinase D promotes plasticity-induced F-actin stabilization in dendritic spines and regulates memory formation. Journal of Cell Biology, 210(5), 771--783.
    10. Müller, D. (2015). Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacology and Therapeutics, 154, 57--66.
    11. Unverdorben, F., Hutt, M., Seifert, O., & Kontermann, R. E. (2015). A fab-selective immunoglobulin-binding domain from streptococcal protein G with improved half-life extension properties. PLoS ONE, 10(10), e0139838.
    12. Schuster, L., Seifert, O., Vollmer, S., Kontermann, R. E., Schlosshauer, B., & Hartmann, H. (2015). Immunoliposomes for Targeted Delivery of an Antifibrotic Drug. Molecular Pharmaceutics, 12(9), 3146--3157.
    13. Herr, R., Köhler, M., Andrlová, H., Weinberg, F., Möller, Y., Halbach, S., Lutz, L., Mastroianni, J., Klose, M., Bittermann, N., Kowar, S., Zeiser, R., Olayioye, M. A., Lassmann, S., Busch, H., Boerries, M., & Brummer, T. (2015). B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Research, 75(1), 216--229.
    14. Fischer, R., & Maier, O. (2015). Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF. Oxidative Medicine and Cellular Longevity, 2015, 1--18.
    15. Rabenhold, M., Steiniger, F., Fahr, A., Kontermann, R. E., & Rüger, R. (2015). Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously. Journal of Controlled Release, 201, 56--67.
    16. Braun, A. C., Hendrick, J., Eisler, S. A., Schmid, S., Hausser, A., & Olayioye, M. A. (2015). The Rho-specific GAP protein DLC3 coordinates endocytic membrane trafficking. Journal of Cell Science, 128(7), 1386--1399.
  10. 2014

    1. Oesterreich, B., Lorenz, B., Schmitter, T., Kontermann, R., Zenn, M., Zimmermann, B., Haake, M., Lorenz, U., & Ohlsen, K. (2014). Characterization of the biological anti-staphylococcal functionality of hUK-66 IgG1, ahumanized monoclonal antibody as substantial component for an immunotherapeutic approach. Human Vaccines and Immunotherapeutics, 10(4), 926--937.
    2. Jaiswal, M., Dvorsky, R., Amin, E., Risse, S. L., Fansa, E. K., Zhang, S. C., Taha, M. S., Gauhar, A. R., Nakhaei-Rad, S., Kordes, C., Koessmeier, K. T., Cirstea, I. C., Olayioye, M. A., Häussinger, D., & Ahmadian, M. R. (2014). Functional cross-talk between ras and rho pathways: A ras-specific gtpase-activating protein (p120RasGAP) competitively inhibits the rhogap activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger. Journal of Biological Chemistry, 289(10), 6839--6849.
    3. Fischer, R., Wajant, H., Kontermann, R., Pfizenmaier, K., & Maier, O. (2014). Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia, 62(2), 272--283.
    4. Wille, C., Köhler, C., Armacki, M., Jamali, A., Gössele, U., Pfizenmaier, K., Seufferlein, T., & Eiseler, T. (2014). Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. Molecular Biology of the Cell, 25(3), 324--36.
    5. Möller, Y., Siegemund, M., Beyes, S., Herr, R., Lecis, D., Delia, D., Kontermann, R., Brummer, T., Pfizenmaier, K., & Olayioye, M. A. (2014). EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells. PLoS ONE, 9(9), e107165.
    6. Kiesgen, S., Liebers, N., Cremer, M., Arnold, U., Weber, T., Keller, A., Herold-Mende, C., Dyckhoff, G., Jäger, D., Kontermann, R. E., Arndt, M. A. E., Krauss, J., & Wu, A. (2014). A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor. Protein Engineering, Design and Selection, 27(10), 331--337.
    7. Rüger, R., Tansi, F. L., Rabenhold, M., Steiniger, F., Kontermann, R. E., Fahr, A., & Hilger, I. (2014). In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes. Journal of Controlled Release, 186, 1--10.
    8. Williams, S. K., Maier, O., Fischer, R., Fairless, R., Hochmeister, S., Stojic, A., Pick, L., Haar, D., Musiol, S., Storch, M. K., Pfizenmaier, K., & Diem, R. (2014). Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS ONE, 9(2), e90117.
    9. Konrath, F., Witt, J., Sauter, T., & Kulms, D. (2014). Identification of New IκBα Complexes by an Iterative Experimental and Mathematical Modeling Approach. PLoS Computational Biology, 10(3), e1003528.
    10. Kermer, V., Hornig, N., Harder, M., Bondarieva, A., Kontermann, R. E., & Muller, D. (2014). Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy. Molecular Cancer Therapeutics, 13(1), 112--121.
    11. Seifert, O., Plappert, A., Fellermeier, S., Siegemund, M., Pfizenmaier, K., & Kontermann, R. E. (2014). Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties. Molecular Cancer Therapeutics, 13(1), 101--111.
    12. Barras, D., Chevalier, N., Zoete, V., Dempsey, R., Lapouge, K., Olayioye, M. A., Michielin, O., & Widmann, C. (2014). A WXW Motif Is Required for the Anticancer Activity of the TAT-RasGAP317–326 Peptide. Journal of Biological Chemistry, 289(34), 23701--23711.
    13. Neumann, S., Hasenauer, J., Pollak, N., & Scheurich, P. (2014). Dominant negative effects of tumor necrosis factor (tnf)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by Formation of heteromeric complexes. Journal of Biological Chemistry, 289(23), 16576--16587.
    14. Seifert, O., Pollak, N., Nusser, A., Steiniger, F., Rüger, R., Pfizenmaier, K., & Kontermann, R. E. (2014). Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles. Bioconjugate Chemistry, 25(5), 879--887.
    15. Lindner, R., Moosmann, A., Dietrich, A., Böttinger, H., Kontermann, R., & Siemann-Herzberg, M. (2014). Process development of periplasmatically produced single chain fragment variable against epidermal growth factor receptor in Escherichia coli. Journal of Biotechnology, 192, 136--145.
    16. Moosmann, A., Müller, E., & Böttinger, H. (2014). Purification of PEGylated Proteins, with the example of PEGylated lysozyme and PEGylated scFv. Methods in Molecular Biology, 1129, 527--538.
    17. Raeth, S., Sacchetti, B., Siegel, G., Mau-Holzmann, U. a, Hansmann, J., Vacun, G., Hauk, T. G., Pfizenmaier, K., & Hausser, A. (2014). A mouse bone marrow stromal cell line with skeletal stem cell characteristics to study osteogenesis in vitro and in vivo. Stem Cells and Development, 23(10), 1097--108.
    18. Siegemund, M., Richter, F., Seifert, O., Unverdorben, F., & Kontermann, R. E. (2014). Expression and Purification of Recombinant Antibody Formats and Antibody Fusion Proteins. In Methods in molecular biology (Clifton, N.J.) (Vol. 1131, pp. 273--295).
    19. Bischoff, A., Huck, B., Keller, B., Strotbek, M., Schmid, S., Boerries, M., Busch, H., Müller, D., & Olayioye, M. A. (2014). MiR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Research, 74(18), 5256--5265.
    20. Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014). Tumor-antigen-binding bispecific antibodies for cancer treatment. Seminars in Oncology, 41(5), 653--660.
    21. Huck, B., Duss, S., Hausser, A., & Olayioye, M. A. (2014). Elevated protein kinase D3 (PKD3) expression supports proliferation of Triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. Journal of Biological Chemistry, 289(6), 3138--3147.
    22. Diebolder, P., Keller, A., Haase, S., Schlegelmilch, A., Kiefer, J. D., Karimi, T., Weber, T., Moldenhauer, G., Kehm, R., Eis-Hübinger, A. M., Jäger, D., Federspil, P. A., Herold-Mende, C., Dyckhoff, G., Kontermann, R. E., Arndt, M. A., & Krauss, J. (2014). Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential. MAbs, 6(1), 130–142.
  11. 2013

    1. Ellwanger, K., & Hausser, A. (2013). Physiological functions of protein kinase D in vivo. IUBMB Life, 65(2), 98--107.
    2. Wajant, H., Gerspach, J., & Pfizenmaier, K. (2013). Engineering death receptor ligands for cancer therapy. Cancer Letters, 332(2), 163--174.
    3. Kakarla, S., Chow, K. K. H., Mata, M., Shaffer, D. R., Song, X. T., Wu, M. F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., & Gottschalk, S. (2013). Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Molecular Therapy, 21(8), 1611--1620.
    4. Hornig, N., Reinhardt, K., Kermer, V., Kontermann, R. E., & Müller, D. (2013). Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. Cancer Immunology, Immunotherapy, 62(8), 1369--1380.
    5. Wahl, K., Siegemund, M., Lehner, F., Vondran, F., Nüssler, A., Länger, F., Krech, T., Kontermann, R., Manns, M. P., Schulze-Osthoff, K., Pfizenmaier, K., & Bantel, H. (2013). Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology, 57(2), 625--636.
    6. Berger, V., Richter, F., Zettlitz, K., Unverdorben, F., Scheurich, P., Herrmann, A., Pfizenmaier, K., & Kontermann, R. E. (2013). An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action. Protein Engineering, Design and Selection, 26(10), 581--587.
    7. Richter, F., Liebig, T., Guenzi, E., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2013). Antagonistic TNF receptor one-specific antibody (ATROSAB): Receptor binding and in vitro bioactivity. PLoS ONE, 8(8), e72156.
    8. Olayioye, M. A., Barisic, S., & Hausser, A. (2013). Multi-level control of actin dynamics by protein kinase D. Cellular Signalling, 25(9), 1739--1747.
    9. Maier, O., Fischer, R., Agresti, C., & Pfizenmaier, K. (2013). TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. Biochemical and Biophysical Research Communications, 440(2), 336--341.
    10. Vörsmann, H., Groeber, F., Walles, H., Busch, S., Beissert, S., Walczak, H., & Kulms, D. (2013). Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death and Disease, 4(7), e719--e719.
    11. Strotbek, M., Florin, L., Koenitzer, J., Tolstrup, A., Kaufmann, H., Hausser, A., & Olayioye, M. A. (2013). Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells. Metabolic Engineering, 20, 157--166.
    12. Kienzle, C., Eisler, S. A., Villeneuve, J., Brummer, T., Olayioye, M. A., & Hausser, A. (2013). PKD controls mitotic Golgi complex fragmentation through a Raf-MEK1 pathway. Molecular Biology of the Cell, 24(3), 222--233.
  12. 2012

    1. Witt, J., Konrath, F., Sawodny, O., Ederer, M., Kulms, D., & Sauter, T. (2012). Analysing the role of UVB-induced translational inhibition and PP2Ac deactivation in NF-κB signalling using a minimal mathematical model. PLoS ONE, 7(7), e40274.
    2. Franz-Wachtel, M., Eisler, S. A., Krug, K., Wahl, S., Carpy, A., Nordheim, A., Pfizenmaier, K., Hausser, A., & Macek, B. (2012). Global Detection of Protein Kinase D-dependent Phosphorylation Events in Nocodazole-treated Human Cells. Molecular & Cellular Proteomics, 11(5), 160--170.
    3. Richter, C., Messerschmidt, S., Holeiter, G., Tepperink, J., Osswald, S., Zappe, A., Branschadel, M., Boschert, V., Mann, D. A., Scheurich, P., & Krippner-Heidenreich, A. (2012). The Tumor Necrosis Factor Receptor Stalk Regions Define Responsiveness to Soluble versus Membrane-Bound Ligand. Molecular and Cellular Biology, 32(13), 2515--2529.
    4. Kempkes, C., Rattenholl, A., Buddenkotte, J., Strozyk, E., Eberle, J., Hausser, A., Cevikbas, F., Schneider, S. W., & Steinhoff, M. (2012). Proteinase-activated receptors 1 and 2 regulate invasive behavior of human melanoma cells via activation of protein kinase D1. Journal of Investigative Dermatology, 132(2), 375--384.
    5. Hutt, M., Färber-Schwarz, A., Unverdorben, F., Richter, F., & Kontermann, R. E. (2012). Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. Journal of Biological Chemistry, 287(7), 4462--4469.
    6. Hornig, N., Kermer, V., Frey, K., Diebolder, P., Kontermann, R. E., & Müller, D. (2012). Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. Journal of Immunotherapy, 35(5), 418--429.
    7. Siegemund, M., Pollak, N., Seifert, O., Wahl, K., Hanak, K., Vogel, A., Nussler, A. K., Göttsch, D., Münkel, S., Bantel, H., Kontermann, R. E., & Pfizenmaier, K. (2012). Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death and Disease, 3(4), e295.
    8. Daub, M., Waldherr, S., Allgöwer, F., Scheurich, P., & Schneider, G. (2012). Death wins against life in a spatially extended model of the caspase-3/8 feedback loop. BioSystems, 108(1–3), 45--51.
    9. Winkel, C., Neumann, S., Surulescu, C., & Scheurich, P. (2012). A minimal mathematical model for the initial molecular interactions of death receptor signalling. Mathematical Biosciences and Engineering, 9(3), 663--683.
    10. Eisler, S. A., Fuchs, Y. F., Pfizenmaier, K., & Hausser, A. (2012). G-PKDrep-live, a genetically encoded FRET reporter to measure PKD activity at the trans-Golgi-network. Biotechnology Journal, 7(1), 148--154.
    11. Müller, D. (2012). Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15. OncoImmunology, 1(7), 1213--1214.
    12. Lopez-Ramirez, M. A., Fischer, R., Torres-Badillo, C. C., Davies, H. A., Logan, K., Pfizenmaier, K., Male, D. K., Sharrack, B., & Romero, I. A. (2012). Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells. The Journal of Immunology, 189(6), 3130--3139.
    13. Kontermann, R. E. (2012). Antibody-cytokine fusion proteins. Archives of Biochemistry and Biophysics, 526(2), 194--205.
    14. Seifert, O., Plappert, A., Heidel, N., Fellermeier, S., Messerschmidt, S. K. E., Richter, F., & Kontermann, R. E. (2012). The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Engineering, Design and Selection, 25(10), 603--612.
    15. Heering, J., Weis, N., Holeiter, M., Neugart, F., Staebler, A., Fehm, T. N., Bischoff, A., Schiller, J., Duss, S., Schmid, S., Korte, T., Herrmann, A., & Olayioye, M. A. (2012). Loss of the ceramide transfer protein augments EGF receptor signaling in breast cancer. Cancer Research, 72(11), 2855--2866.
    16. Kontermann, R. E. (2012). Dual targeting strategies with bispecific antibodies. MAbs, 4(2), 182--197.
    17. Schildknecht, S., Kirner, S., Henn, A., Gasparic, K., Pape, R., Efremova, L., Maier, O., Fischer, R., & Leist, M. (2012). Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. Altex, 29(3), 261--274.
    18. Moosmann, A., Gerlach, E., Lindner, R., & Böttinger, H. (2012). Purification of a PEGylated single chain Fv. Journal of Chromatography A, 1236, 90--96.
    19. Olayioye, M. A., & Hausser, A. (2012). Integration of non-vesicular and vesicular transport processes at the Golgi complex by the PKD-CERT network. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1821(8), 1096--1103.
    20. Hasenauer, J., Heinrich, J., Doszczak, M., Scheurich, P., Weiskopf, D., & Allgöwer, F. (2012). A visual analytics approach for models of heterogeneous cell populations. Eurasip Journal on Bioinformatics and Systems Biology, 2012(1), 4.
    21. Kermer, V., Baum, V., Hornig, N., Kontermann, R. E., & Müller, D. (2012). An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 \textlessi\textgreatertrans\textless/i\textgreater -Presentation at the Tumor Site. Molecular Cancer Therapeutics, 11(6), 1279--1288.
    22. Holeiter, G., Bischoff, A., Braun, A. C., Huck, B., Erlmann, P., Schmid, S., Herr, R., Brummer, T., & Olayioye, M. A. (2012). The RhoGAP protein deleted in liver cancer 3 (DLC3) is essential for adherens junctions integrity. Oncogenesis, 1(6), e13--e13.
    23. Huck, B., Kemkemer, R., Franz-Wachtel, M., Macek, B., Hausser, A., & Olayioye, M. A. (2012). GIT1 Phosphorylation on Serine 46 by PKD3 regulates paxillin trafficking and cellular protrusive activity. Journal of Biological Chemistry, 287(41), 34604--34613.
    24. Unverdorben, F., Färber-Schwarz, A., Richter, F., Hutt, M., & Kontermann, R. E. (2012). Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A. Protein Engineering, Design and Selection, 25(2), 81--88.
    25. Neumann, S., Bidon, T., Branschädel, M., Krippner-Heidenreich, A., Scheurich, P., & Doszczak, M. (2012). The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity. PLoS ONE, 7(8), e42526.
    26. Mack, K., Rüger, R., Fellermeier, S., Seifert, O., & Kontermann, R. E. (2012). Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes. Antibodies, 1(3), 199--214.
  13. 2011

    1. Krenz, B., Neugart, F., Kleinow, T., & Jeske, H. (2011). Self-interaction of Abutilon mosaic virus replication initiator protein (Rep) in plant cell nuclei. Virus Research, 161(2), 194--197.
    2. Kontermann, R. E. (2011). Strategies for extended serum half-life of protein therapeutics. Current Opinion in Biotechnology, 22(6), 868--876.
    3. Gerspach, J., Pfizenmaier, K., & Wajant, H. (2011). Therapeutic Targeting of CD95 and the TRAIL Death Receptors. Recent Patents on Anti-Cancer Drug Discovery, 6(3), 294--310.
    4. Pfizenmaier, K., & Szymkowski, D. E. (2011). Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family. Adv Exp Med Biol, 691, 487--491.
    5. Barisić, S., Nagel, A. C., Franz-Wachtel, M., MacEk, B., Preiss, A., Link, G., Maier, D., & Hausser, A. (2011). Phosphorylation of ser 402 impedes phosphatase activity of slingshot 1. EMBO Reports, 12(6), 527--533.
    6. Chertoff, M., Paolo, N. D., Schoeneberg, A., Depino, A., Ferrari, C., Wurst, W., Pfizenmaier, K., Eisel, U., & Pitossi, F. (2011). Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice. Experimental Neurology, 227(2), 237--251.
    7. Schliemann, M., Bullinger, E., Borchers, S., Allgöwer, F., Findeisen, R., & Scheurich, P. (2011). Heterogeneity reduces sensitivity of cell death for TNF-Stimuli. BMC Systems Biology, 5, 204.
    8. Gerspach, J., Schneider, B., Müller, N., Otz, T., Wajant, H., & Pfizenmaier, K. (2011). Genetic engineering of death ligands for improvement of therapeutic activity. Advances in Experimental Medicine and Biology, 691, 507--519.
    9. Scholz, R. P., Gustafsson, J. O. R., Hoffmann, P., Jaiswal, M., Ahmadian, M. R., Eisler, S. A., Erlmann, P., Schmid, S., Hausser, A., & Olayioye, M. A. (2011). The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Experimental Cell Research, 317(4), 496--503.
    10. Wajant, H., & Scheurich, P. (2011). TNFR1-induced activation of the classical NF-κB pathway. FEBS Journal, 278(6), 862--876.
    11. Dengler, M. A., Staiger, A. M., Gutekunst, M., Hofmann, U., Doszczak, M., Scheurich, P., Schwab, M., Aulitzky, W. E., & van der Kuip, H. (2011). Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. PLoS ONE, 6(9), e25139.
    12. Hörnle, M., Peters, N., Thayaparasingham, B., Vörsmann, H., Kashkar, H., & Kulms, D. (2011). Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene, 30(5), 575--587.
    13. Ziegler, S., Eiseler, T., Scholz, R.-P., Beck, A., Link, G., & Hausser, A. (2011). A novel protein kinase D phosphorylation site in the tumor suppressor Rab interactor 1 is critical for coordination of cell migration. Molecular Biology of the Cell, 22(5), 570--580.
    14. Ranzinger, J., Rustom, A., Abel, M., Leyh, J., Kihm, L., Witkowski, M., Scheurich, P., Zeier, M., & Schwenger, V. (2011). Nanotube action between human mesothelial cells reveals novel aspects of inflammatory responses. PLoS ONE, 6(12), e29537.
    15. Moosmann, A., Blath, J., Lindner, R., Müller, E., & Böttinger, H. (2011). Aldehyde PEGylation kinetics: A standard protein versus a pharmaceutically relevant single chain variable fragment. Bioconjugate Chemistry, 22(8), 1545--1558.
    16. Hasenauer, J., Waldherr, S., Doszczak, M., Radde, N., Scheurich, P., & Allgöwer, F. (2011). Identification of models of heterogeneous cell populations from population snapshot data. BMC Bioinformatics, 12, 125.
    17. Gehrmann, M., Doß, B. T., Wagner, M., Zettlitz, K. A., Kontermann, R. E., Foulds, G., Pockley, A. G., & Multhoff, G. (2011). A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. Journal of Immunological Methods, 371(1–2), 8--17.
    18. Niessner, H., Beck, D., Sinnberg, T., Lasithiotakis, K., MacZey, E., Gogel, J., Venturelli, S., Berger, A., Mauthe, M., Toulany, M., Flaherty, K., Schaller, M., Schadendorf, D., Proikas-Cezanne, T., Schittek, B., Garbe, C., Kulms, D., & Meier, F. (2011). The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. Journal of Investigative Dermatology, 131(2), 468--479.
    19. Witt, J., Barisic, S., Sawodny, O., Ederer, M., Kulms, D., & Sauter, T. (2011). Modeling time delay in the NFκB signaling pathway following low dose IL-1 stimulation. EURASIP Journal on Bioinformatics & Systems Biology, 2011(1), 3.
    20. Fischer, R., Maier, O., Siegemund, M., Wajant, H., Scheurich, P., & Pfizenmaier, K. (2011). A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS ONE, 6(11), e27621.
    21. Fischer, R., Maier, O., Naumer, M., Krippner-Heidenreich, A., Scheurich, P., & Pfizenmaier, K. (2011). Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFκB pathway. Cellular Signalling, 23(1), 161--170.
    22. Ellwanger, K., Kienzle, C., Lutz, S., Jin, Z., Wiekowski, M. T., Pfizenmaier, K., & Hausser, A. (2011). Protein kinase D controls voluntary-running-induced skeletal muscle remodelling. Biochemical Journal, 440(3), 327--324.
  14. 2010

    1. Schneider, B., Münkel, S., Krippner-Heidenreich, A., Grunwald, I., Wels, W. S., Wajant, H., Pfizenmaier, K., & Gerspach, J. (2010). Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death and Disease, 1(8), e68.
    2. Becker, E., Florin, L., Pfizenmaier, K., & Kaufmann, H. (2010). Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. Journal of Biotechnology, 146(4), 198--206.
    3. Müller, E., Josic, D., Schröder, T., & Moosmann, A. (2010). Solubility and binding properties of PEGylated lysozyme derivatives with increasing molecular weight on hydrophobic-interaction chromatographic resins. Journal of Chromatography A, 1217(28), 4696--4703.
    4. Zettlitz, K. A., Lorenz, V., Landauer, K., Münkel, S., Herrmann, A., Scheurich, P., Pfizenmaier, K., & Kontermann, R. E. (2010). ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs, 2(6), 639--647.
    5. Gerken, M., Krippner-Heidenreich, A., Steinert, S., Willi, S., Neugart, F., Zappe, A., Wrachtrup, J., Tietz, C., & Scheurich, P. (2010). Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors. Biochimica et Biophysica Acta - Biomembranes, 1798(6), 1081--1089.
    6. Barisic, S., Schmidt, C., Walczak, H., & Kulms, D. (2010). Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFκB activation via Src-dependent blockade of PP2A. Biochemical Pharmacology, 80(4), 439--447.
    7. Murphy, N. C., Biankin, A. V., Millar, E. K. A., McNeil, C. M., O’Toole, S. A., Segara, D., Crea, P., Olayioye, M. A., Lee, C. S., Fox, S. B., Morey, A. L., Christie, M., Musgrove, E. A., Daly, R. J., Lindeman, G. J., Henshall, S. M., Visvader, J. E., & Sutherland, R. L. (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126(6), 1445--1453.
    8. Branschädel, M., Aird, A., Zappe, A., Tietz, C., Krippner-Heidenreich, A., & Scheurich, P. (2010). Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: Conformational stabilization of CRD2 and control of receptor responsiveness. Cellular Signalling, 22(3), 404--414.
    9. Hasenauer, J., Waldherr, S., Radde, N., Doszczak, M., Scheurich, P., & Allgöwer, F. (2010). A maximum likelihood estimator for parameter distributions in heterogeneous cell populations. Procedia Computer Science, 1(1), 1655--1663.
    10. Baum, P., Fundel-Clemens, K., Kreuz, S., Kontermann, R. E., Weith, A., Mennerich, D., & Rippmann, J. F. (2010). Off-target analysis of control siRNA molecules reveals important differences in the cytokine profile and inflammation response of human fibroblasts. Oligonucleotides, 20(1), 17--26.
    11. Baum, P., Schmid, R., Ittrich, C., Rust, W., Fundel-Clemens, K., Siewert, S., Baur, M., Mara, L., Gruenbaum, L., Heckel, A., Eils, R., Kontermann, R. E., Roth, G. J., Gantner, F., Schnapp, A., Park, J. E., Weith, A., Quast, K., & Mennerich, D. (2010). Phenocopy - a strategy to qualify chemical compounds during hit-to-lead and/or lead optimization. PLoS ONE, 5(12), 1--15.
    12. Eiseler, T., Hausser, A., De Kimpe, L., Van Lint, J., & Pfizenmaier, K. (2010). Protein kinase D controls actin polymerization and cell motility through phosphorylation of cortactin. Journal of Biological Chemistry, 285(24), 18672--18683.
    13. Waldherr, S., Hasenauer, J., Doszczak, M., Scheurich, P., & Allgöwer, F. (2010). Global uncertainty analysis for a model of TNF-induced NF-κB signalling. In Lecture Notes in Control and Information Sciences (Vol. 407, pp. 365--377). Springer, Berlin, Heidelberg.
    14. Müller, D., & Kontermann, R. E. (2010). Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs, 24(2), 89--98.
    15. Brandt, S., Ellwanger, K., Beuter-Gunia, C., Schuster, M., Hausser, A., Schmitz, I., & Beer-Hammer, S. (2010). SLy2 targets the nuclear SAP30/HDAC1 complex. International Journal of Biochemistry and Cell Biology, 42(9), 1472--1481.
    16. Hopp, J., Hornig, N., Zettlitz, K. A., Schwarz, A., Fuß, N., Müller, D., & Kontermann, R. E. (2010). The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Engineering, Design and Selection, 23(11), 827--834.
    17. Zettlitz, K. A., Seitter, J., Müller, D., & Kontermann, R. E. (2010). Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70). Molecular Biotechnology, 46(3), 265--278.
    18. Hasenauer, J., Waldherr, S., Doszczak, M., Scheurich, P., & Allgöwer, F. (2010). Density-based modeling and identification of biochemical networks in cell populations. IFAC Proceedings Volumes (IFAC-PapersOnline), 9(PART 1), 320--325.
    19. Rothdiener, M., Müller, D., Castro, P. G., Scholz, A., Schwemmlein, M., Fey, G., Heidenreich, O., & Kontermann, R. E. (2010). Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. Journal of Controlled Release, 144(2), 251--258.
    20. Smolders, I., Smets, I., Maier, O., VandeVen, M., Steels, P., & Ameloot, M. (2010). Simvastatin interferes with process outgrowth and branching of oligodendrocytes. Journal of Neuroscience Research, 88(15), 3361--3375.
    21. Moosmann, A., Christel, J., Boettinger, H., & Mueller, E. (2010). Analytical and preparative separation of PEGylated lysozyme for the characterization of chromatography media. Journal of Chromatography A, 1217(2), 209--215.
    22. Boschert, V., Krippner-Heidenreich, A., Branschädel, M., Tepperink, J., Aird, A., & Scheurich, P. (2010). Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2. Cellular Signalling, 22(7), 1088--1096.
    23. Anliker, B., Abel, T., Kneissl, S., Hlavaty, J., Caputi, A., Brynza, J., Schneider, I. C., Münch, R. C., Petznek, H., Kontermann, R. E., Koehl, U., Johnston, I. C. D., Keinänen, K., Müller, U. C., Hohenadl, C., Monyer, H., Cichutek, K., & Buchholz, C. J. (2010). Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nature Methods, 7, 929--.
    24. Kontermann, R. E. (2010). Alternative antibody formats. Current Opinion in Molecular Therapeutics, 12(2), 176--183.
    25. Rothdiener, M., Beuttler, J., Messerschmidt, S. K., & Kontermann, R. E. (2010). Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods in Molecular Biology (Clifton, N.J.), 624, 295--308.
    26. Joffroy, C. M., Buck, M. B., Stope, M. B., Popp, S. L., Pfizenmaier, K., & Knabbe, C. (2010). Antiestrogens induce transforming growth factor $\beta$-mediated immunosuppression in breast cancer. Cancer Research, 70(4), 1314--1322.
  15. 2009

    1. Schlatter, R., Schmich, K., Vizcarra, I. A., Scheurich, P., Sauter, T., Borner, C., Ederer, M., Merfort, I., & Sawodny, O. (2009). ON/OFF and beyond - A Boolean model of apoptosis. PLoS Computational Biology, 5(12), e1000595.
    2. Beuttler, J., Rothdiener, M., Müller, D., Frejd, F. Y., & Kontermann, R. E. (2009). Targeting of Epidermal Growth Factor Receptor (EGFR)-Expressing Tumor Cells with Sterically Stabilized Affibody Liposomes (SAL). Bioconjugate Chemistry, 20(6), 1201–1208.
    3. Ranzinger, J., Krippner-Heidenreich, A., Haraszti, T., Bock, E., Tepperink, J., Spatz, J. P., & Scheurich, P. (2009). Nanoscale arrangement of apoptotic ligands reveals a demand for a minimal lateral distance for efficient death receptor activation. Nano Letters, 9(12), 4240--4245.
    4. Gerspach, J., Wajant, H., & Pfizenmaier, K. (2009). Death ligands designed to kill: Development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results and Problems in Cell Differentiation, 49, 241--273.
    5. Gerspach, J., Pfizenmaier, K., & Wajant, H. (2009). Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. BioFactors, 35(4), 364--372.
    6. Erlmann, P., Schmid, S., Horenkamp, F. A., Geyer, M., Pomorski, T. G., & Olayioye, M. A. (2009). DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Molecular Biology of the Cell, 20(20), 4400--4411.
    7. Sinnberg, T., Lasithiotakis, K., Niessner, H., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Campos, M., Gogel, J., Garbe, C., & Meier, F. (2009). Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide. Journal of Investigative Dermatology, 129(6), 1500--1515.
    8. Thayaparasingham, B., Kunz, A., & Kulms, D. (2009). Sensitization of melanoma cells to TRAIL by UVB-induced and NF-κB-mediated downregulation of xIAP. Oncogene, 28(3), 345--362.
    9. Kontermann, R. E. (2009). Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs, 23(2), 93--109.
    10. Messerschmidt, S. K. E., Musyanovych, A., Altvater, M., Scheurich, P., Pfizenmaier, K., Landfester, K., & Kontermann, R. E. (2009). Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells. Journal of Controlled Release, 137(1), 69--77.
    11. Peterburs, P., Heering, J., Link, G., Pfizenmaier, K., Olayioye, M. A., & Hausser, A. (2009). Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Research, 69(14), 5634--5638.
    12. Wicovsky, A., Henkler, F., Salzmann, S., Scheurich, P., Kneitz, C., & Wajant, H. (2009). Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation. Oncogene, 28(15), 1769--1781.
    13. Czöndör, K., Ellwanger, K., Fuchs, Y. F., Lutz, S., Gulyás, M., Mansuy, I. M., Hausser, A., Pfizenmaier, K., & Schlett, K. (2009). Protein kinase D controls the integrity of Golgi apparatus and the maintenance of dendritic arborization in hippocampal neurons. Molecular Biology of the Cell, 20(7), 2108--20.
    14. Florin, L., Pegel, A., Becker, E., Hausser, A., Olayioye, M. A., & Kaufmann, H. (2009). Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells. Journal of Biotechnology, 141(1–2), 84--90.
    15. Fuchs, Y. F., Eisler, S. A., Link, G., Schlicker, O., Bunt, G., Pfizenmaier, K., & Hausser, A. (2009). A Golgi PKD activity reporter reveals a crucial role of PKD in nocodazole-induced Golgi dispersal. Traffic, 10(7), 858--867.
    16. Stork, R., Campigna, E., Robert, B., Müller, D., & Kontermann, R. E. (2009). Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. Journal of Biological Chemistry, 284(38), 25612--25619.
    17. Wyzgol, A., Muller, N., Fick, A., Munkel, S., Grigoleit, G. U., Pfizenmaier, K., & Wajant, H. (2009). Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand. The Journal of Immunology, 183(3), 1851--1861.
    18. Kontermann, R. E., Scheurich, P., & Pfizenmaier, K. (2009). Antagonists of TNF action: clinical experience and new developments. Expert Opinion on Drug Discovery, 4(3), 279--292.
    19. Heering, J., Erlmann, P., & Olayioye, M. A. (2009). Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Experimental Cell Research, 315(15), 2505--2514.
    20. Witt, J., Barisic, S., Schumann, E., Allgöwer, F., Sawodny, O., Sauter, T., & Kulms, D. (2009). Mechanism of PP2A-mediated IKKβ dephosphorylation: A systems biological approach. BMC Systems Biology, 3, 71.
    21. Ahmadvand, D., Rasaee, M. J., Rahbarizadeh, F., Kontermann, R. E., & Sheikholislami, F. (2009). Cell selection and characterization of a novel human endothelial cell specific nanobody. Molecular Immunology, 46(8–9), 1814--1823.
    22. Scholz, R.-P., Regner, J., Theil, A., Erlmann, P., Holeiter, G., Jähne, R., Schmid, S., Hausser, A., & Olayioye, M. a. (2009). DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. Journal of Cell Science, 122(Pt 1), 92--102.
    23. Breindl, C., Waldherr, S., Hausser, A., & Allgöwer, F. (2009). MODELING COFILIN MEDIATED REGULATION OF CELL MIGRATION AS A BIOCHEMICAL TWO-INPUT SWITCH. Proc.of the 3rd Foundations of Systems Biology in Engineering (FOSBE), 60--63.
    24. Cowell, C. F., Doppler, H., Yan, I. K., Hausser, A., Umezawa, Y., & Storz, P. (2009). Mitochondrial diacylglycerol initiates protein-kinase-D1-mediated ROS signaling. Journal of Cell Science, 122(7), 919--928.
  16. 2008

    1. Holeiter, G., Heering, J., Erlmann, P., Schmid, S., Jähne, R., & Olayioye, M. A. (2008). Deleted in liver cancer 1 controls cell migration through a dia1-dependent signaling pathway. Cancer Research, 68(21), 8743--8751.
    2. Kontermann, R. E., Münkel, S., Neumeyer, J., Müller, D., Branschädel, M., Scheurich, P., & Pfizenmaier, K. (2008). A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. Journal of Immunotherapy, 31(3), 225--234.
    3. Ellwanger, K., Pfizenmaier, K., Lutz, S., & Hausser, A. (2008). Expression patterns of protein kinase D 3 during mouse development. BMC Developmental Biology, 8, 47.
    4. Stork, R., Zettlitz, K. A., Müller, D., Rether, M., Hanisch, F. G., & Kontermann, R. E. (2008). N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. Journal of Biological Chemistry, 283(12), 7804--7812.
    5. Singer-Krüger, B., Lasić, M., Bürger, A. M., Haußer, A., Pipkorn, R., & Wang, Y. (2008). Yeast and human Ysl2p/hMon2 interact with Gga adaptors and mediate their subcellular distribution. EMBO Journal, 27(10), 1423--1435.
    6. Barisic, S., Strozyk, E., Peters, N., Walczak, H., & Kulms, D. (2008). Identification of PP2A as a crucial regulator of the NF-$\kappa$B feedback loop: Its inhibition by UVB turns NF-κB into a pro-apoptotic factor. Cell Death and Differentiation, 15(11), 1681--1690.
    7. Chang, H. H., Wang, W., Bong, S. J., Wong, C., Hausser, A., Pfizenmaier, K., McKinsey, T. A., Olson, E. N., & Jin, Z. G. (2008). Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. Journal of Biological Chemistry, 283(21), 14590--14599.
    8. Krippner-Heidenreich, A., Grunwald, I., Zimmermann, G., Kuhnle, M., Gerspach, J., Sterns, T., Shnyder, S. D., Gill, J. H., Mannel, D. N., Pfizenmaier, K., & Scheurich, P. (2008). Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity. The Journal of Immunology, 180(12), 8176--8183.
    9. Müller, N., Wyzgol, A., Münkel, S., Pfizenmaier, K., & Wajant, H. (2008). Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS Journal, 275(9), 2296--2304.
    10. Messerschmidt, S. K. E., Kolbe, A., Müller, D., Knoll, M., Pleiss, J., & Kontermann, R. E. (2008). Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling. Bioconjugate Chemistry, 19(1), 362--369.
    11. Müller, D., Frey, K., & Kontermann, R. E. (2008). A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. Journal of Immunotherapy, 31(8), 714--722.
    12. Müller, D., Trunk, G., Sichelstiel, A., Zettlitz, K. A., Quintanilla, M., & Kontermann, R. E. (2008). Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. Journal of Immunological Methods, 339(1), 90--98.
    13. Müller, E., & Faude, A. (2008). Investigation of salt properties with electro-acoustic measurements and their effect on dynamic binding capacity in hydrophobic interaction chromatography. Journal of Chromatography A, 1177(2), 215--225.
    14. Lasithiotakis, K. G., Sinnberg, T. W., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Garbe, C., & Meier, F. E. (2008). Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells. Journal of Investigative Dermatology, 128(8), 2013--2023.
    15. Johnson, T. S., Mahnke, K., Storn, V., Schönfeld, K., Ring, S., Nettelbeck, D. M., Haisma, H. J., Le Gall, F., Kontermann, R. E., & Enk, A. H. (2008). Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clinical Cancer Research, 14(24), 8169--8177.
    16. BECKER, E., FLORIN, L., PFIZENMAIER, K., & KAUFMANN, H. (2008). An XBP-1 dependent bottle-neck in production of IgG subtype antibodies in chemically defined serum-free Chinese hamster ovary (CHO) fed-batch processes. Journal of Biotechnology, 135(2), 217--223.
  17. 2007

    1. Olayioye, M. A., Buchholz, M., Schmid, S., Schöffler, P., Hoffmann, P., & Pomorski, T. (2007). Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity. Journal of Biological Chemistry, 282(31), 22492--22498.
    2. Eissing, T., Waldherr, S., Allgöwer, F., Scheurich, P., & Bullinger, E. (2007). Response to bistability in apoptosis: Roles of Bax, Bcl-2, and mitochondrial permeability transition pores. Biophysical Journal, 92(9), 3332--3334.
    3. Eiseler, T., Schmid, M. A., Topbas, F., Pfizenmaier, K., & Hausser, A. (2007). PKD is recruited to sites of actin remodelling at the leading edge and negatively regulates cell migration. FEBS Letters, 581(22), 4279--4287.
    4. Baum, P., Müller, D., Rüger, R., & Kontermann, R. E. (2007). Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. Journal of Drug Targeting, 15(6), 399--406.
    5. Eißing, T., Waldherr, S., Allgöwer, F., Scheurich, P., & Bullinger, E. (2007). Steady state and (bi-) stability evaluation of simple protease signalling networks. Biosystems, 90(3), 591--601.
    6. Berg, D., Lehne, M., Müller, N., Siegmund, D., Münkel, S., Sebald, W., Pfizenmaier, K., & Wajant, H. (2007). Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death and Differentiation, 14(12), 2021--2034.
    7. Stork, R., Müller, D., & Kontermann, R. E. (2007). A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Engineering, Design and Selection, 20(11), 569--576.
    8. Fugmann, T., Hausser, A., Schöffler, P., Schmid, S., Pfizenmaier, K., & Olayioye, M. A. (2007). Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein. Journal of Cell Biology, 178(1), 15--22.
    9. Faude, A., Zacher, D., Müller, E., & Böttinger, H. (2007). Fast determination of conditions for maximum dynamic capacity in cation-exchange chromatography of human monoclonal antibodies. Journal of Chromatography A, 1161(1–2), 29--35.
    10. Xu, X., Ha, C. H., Wong, C., Wang, W., Hausser, A., Pfizenmaier, K., Olson, E. N., McKinsey, T. A., & Jin, Z. G. (2007). Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(11), 2355--2362.
    11. Witt, J., Husser, S., Kulms, D., Barisic, S., Sawodny, O., & Sauter, T. (2007). Modeling of IL-1 induced NF-κB signaling and analysis of additional UVB influence. Proceedings of the SICE Annual Conference, 1353--1358.
    12. Maier, D., Nagel, A. C., Gloc, H., Hausser, A., Kugler, S. J., Wech, I., & Preiss, A. (2007). Protein Kinase D regulates several aspects of development in Drosophila melanogaster. BMC Developmental Biology, 7, 74.
    13. Meier, F., Busch, S., Lasithiotakis, K., Kulms, D., Garbe, C., Maczey, E., Herlyn, M., & Schittek, B. (2007). Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. British Journal of Dermatology, 156(6), 1204--1213.
    14. Müller, D., & Kontermann, R. E. (2007). Recombinant bispecific antibodies for cellular cancer immunotherapy. Current Opinion in Molecular Therapeutics, 9(4), 319.
    15. Hesse, A., Kosmides, D., Kontermann, R. E., & Nettelbeck, D. M. (2007). Tropism Modification of Adenovirus Vectors by Peptide Ligand Insertion into Various Positions of the Adenovirus Serotype 41 Short-Fiber Knob Domain. Journal of Virology, 81(6), 2688--2699.
    16. Müller, D., Karle, A., Meißburger, B., Höfig, I., Stork, R., & Kontermann, R. E. (2007). Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. Journal of Biological Chemistry, 282(17), 12650--12660.
  18. 2006

    1. Kulms, D., & Schwarz, T. (2006). NF-κB and Cytokines. Vitamins and Hormones, 74, 283--300.
    2. Hausser, A., Link, G., Hoene, M., Russo, C., Selchow, O., & Pfizenmaier, K. (2006). Phospho-specific binding of 14-3-3 proteins to phosphatidylinositol 4-kinase III β protects from dephosphorylation and stabilizes lipid kinase activity. Journal of Cell Science, 119(17), 3613--3621.
    3. Kontermann, R. E. (2006). Immunoliposomes for cancer therapy. Current Opinion in Molecular Therapeutics, 8(1), 39--45.
    4. Maier, D., Hausser, A., Nagel, A. C., Link, G., Kugler, S. J., Wech, I., Pfizenmaier, K., & Preiss, A. (2006). Drosophila protein kinase D is broadly expressed and a fraction localizes to the Golgi compartment. Gene Expression Patterns, 6(8), 849--856.
    5. Rüger, R., Müller, D., Fahr, A., & Kontermann, R. E. (2006). In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. Journal of Drug Targeting, 14(8), 576--582.
    6. Assohou-Luty, C., Gerspach, J., Siegmund, D., Müller, N., Huard, B., Tiegs, G., Pfizenmaier, K., & Wajant, H. (2006). A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. Journal of Molecular Medicine, 84(9), 785--797.
    7. Gerspach, J., Németh, J., Münkel, S., Wajant, H., & Pfizenmaier, K. (2006). Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunology, Immunotherapy, 55(12), 1590--1600.
    8. Beisner, J., Buck, M. B., Fritz, P., Dippon, J., Schwab, M., Brauch, H., Zugmaier, G., Pfizenmaier, K., & Knabbe, C. (2006). A Novel Functional Polymorphism in the Transforming Growth Factor-β2 Gene Promoter and Tumor Progression in Breast Cancer. Cancer Research, 66(15), 7554--7561.
    9. Strozyk, E., Pöppelmann, B., Schwarz, T., & Kulms, D. (2006). Differential effects of NF-κB on apoptosis induced by DNA-damaging agents: The type of DNA damage determines the final outcome. Oncogene, 25(47), 6239--6251.
    10. Watermann, I., Gerspach, J., Lehne, M., Seufert, J., Schneider, B., Pfizenmaier, K., & Wajant, H. (2006). Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death And Differentiation, 14, 765--.
    11. Gerspach, J., Müller, D., Münkel, S., Selchow, O., Nemeth, J., Noack, M., Petrul, H., Menrad, A., Wajant, H., & Pfizenmaier, K. (2006). Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death and Differentiation, 13(2), 273--284.
To the top of the page